These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2525981)

  • 21. Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction.
    Brier ME; Sloan RS; Aronoff GR
    Clin Pharmacol Ther; 1995 Jun; 57(6):622-7. PubMed ID: 7781261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of etodolac in patients with moderate renal impairment compared with normal subjects.
    Brater DC; Anderson SA; Brown-Cartwright D; Toto RD; Chen A; Jacob GB
    Clin Pharmacol Ther; 1985 Dec; 38(6):674-9. PubMed ID: 2933206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
    al-Ghamdi MS; al-Mohanna FA; al-Mustafa ZH; al-Saeed IS
    Eur J Clin Pharmacol; 1992; 43(2):197-9. PubMed ID: 1425878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Investigation of plasma levels of etodolac and urine PGE2 in patients with rheumatoid arthritis].
    Matsunaga K; Yawata M; Hagiya N; Tani K; Kawai T; Nagaoka S; Aoki A; Nakamura M; Senuma A; Motoji K; Chiba J; Ishigatsubo Y
    Ryumachi; 1999 Aug; 39(4):634-44. PubMed ID: 10536480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global safety of etodolac: reports from worldwide postmarketing surveillance studies.
    Serni U
    Rheumatol Int; 1990; 10 Suppl():23-7. PubMed ID: 2150568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic study of esomeprazole in patients with hepatic impairment.
    Sjövall H; Björnsson E; Holmberg J; Hasselgren G; Röhss K; Hassan-Alin M
    Eur J Gastroenterol Hepatol; 2002 May; 14(5):491-6. PubMed ID: 11984146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
    Price TM; Dupuis RE; Carr BR; Stanczyk FZ; Lobo RA; Droegemueller W
    Am J Obstet Gynecol; 1993 May; 168(5):1400-6. PubMed ID: 8498419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers.
    Türck D; Schwarz A; Höffler D; Narjes HH; Nehmiz G; Heinzel G
    Eur J Clin Pharmacol; 1996; 51(3-4):309-13. PubMed ID: 9010704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An updated safety profile of etodolac in several thousand patients.
    Schattenkirchner M
    Eur J Rheumatol Inflamm; 1990; 10(1):56-65. PubMed ID: 2146132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma tenoxicam concentrations after single and multiple oral doses.
    Crevoisier C; Heizmann P; Forgo I; Dubach UC
    Eur J Drug Metab Pharmacokinet; 1989; 14(1):23-7. PubMed ID: 2788089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics.
    Brater DC; Anderson SA; Brown-Cartwright D; Toto RD
    Am J Kidney Dis; 1986 Nov; 8(5):351-5. PubMed ID: 2947456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of sustained-release etodolac.
    Benet LZ
    Rheumatol Int; 1993; 13(2 Suppl):S3-5. PubMed ID: 8210922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of single and multiple doses of tiaprofenic acid in elderly patients with arthritis.
    Hosie J; Hosie GA
    Eur J Clin Pharmacol; 1987; 32(1):93-5. PubMed ID: 3582474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The stereoselective pharmacokinetics of etodolac in young and elderly subjects, and after cholecystectomy.
    Brocks DR; Jamali F; Russell AS; Skeith KJ
    J Clin Pharmacol; 1992 Nov; 32(11):982-9. PubMed ID: 1474171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
    Frost RW; Lettieri JT; Krol G; Shamblen EC; Lasseter KC
    Clin Pharmacol Ther; 1989 Jun; 45(6):608-16. PubMed ID: 2731404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis.
    Boni JP; Korth-Bradley JM; Martin P; Simcoe DK; Richards LS; Rennebohm R; Walson PD
    Clin Ther; 1999 Oct; 21(10):1715-24. PubMed ID: 10566567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.